Illinois Expands Medicaid Coverage for Sera Prognostics' Preterm Birth Test — Sera Prognostics, Inc. (The Pregnancy Company)

Event summary

Illinois amended its Public Aid Code to require Medicaid coverage for proteomic blood tests, including Sera Prognostics' PreTRM® Test, aimed at identifying preterm birth risk.
The legislation also mandates coverage for associated care management services and interventions proven to improve patient outcomes.
Preterm birth accounts for 13,042 births annually in Illinois, with Medicaid financing nearly half of all U.S. births.
Sera's PreTRM® Test is the only broadly validated, commercially available blood-based test for spontaneous preterm birth risk prediction.

The big picture

Illinois' move reflects growing recognition of proteomic testing as a cost-effective tool for improving neonatal outcomes, addressing the $25 billion annual healthcare burden of preterm birth complications in the U.S. The policy shift aligns with broader trends toward evidence-based prenatal care and value-based reimbursement models. Sera Prognostics stands to benefit from expanded access to its validated diagnostic, though execution risks remain tied to state-level implementation.

What we're watching

Implementation Pace: The speed at which Illinois finalizes and rolls out coverage frameworks for proteomic testing will determine Sera's near-term revenue impact.
Market Expansion: Whether other states follow Illinois' lead in mandating Medicaid coverage for preterm birth risk assessment tools.
Clinical Adoption: The extent to which healthcare providers integrate Sera's PreTRM® Test into standard prenatal care protocols.